Active substance:
Piperacillin sodium + Tazobactam sodium
Pharmacotherapeutic group:
Antibacterials for systemic use, Combinations of penicillins incl. beta-lactamase inhibitors;
ATC code: J01CR05
Mechanism of action:
Piperacillin, a broad-spectrum, semisynthetic penicillin exerts bactericidal activity by inhibition of both septum and cell-wall synthesis.
Tazobactam, a beta-lactam structurally related to penicillins, is an inhibitor of many beta-lactamases, which commonly cause resistance to penicillins and cephalosporins but it does not inhibit AmpC enzymes or metallo beta-lactamases. Tazobactam extends the antibiotic spectrum of piperacillin to include many beta-lactamase-producing bacteria that have acquired resistance to piperacillin alone.
Therapeutic indications:
Piperacillin plus Tazobactam Eberth is indicated for the treatment of the following infections in adults and children over 2 years of age:
Adults and adolescents
- Severe pneumonia including hospital-acquired and ventilator associated pneumonia
- Complicated urinary tract infections (including pyelonephritis)
- Complicated intra-abdominal infections
- Complicated skin and soft tissue infections (including diabetic foot infections)
Treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above.
Piperacillin plusTazobactam Eberth may be used in the management of neutropenic patients with fever suspected to be due to a bacterial infection.
Children 2 to 12 years of age
- Complicated intra-abdominal infections
Piperacillin plus Tazobactam Eberth may be used in the management of neutropenic children with fever suspected to be due to a bacterial infection.